DE69619868D1 - Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung - Google Patents

Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung

Info

Publication number
DE69619868D1
DE69619868D1 DE69619868T DE69619868T DE69619868D1 DE 69619868 D1 DE69619868 D1 DE 69619868D1 DE 69619868 T DE69619868 T DE 69619868T DE 69619868 T DE69619868 T DE 69619868T DE 69619868 D1 DE69619868 D1 DE 69619868D1
Authority
DE
Germany
Prior art keywords
pct
pharmaceutical compositions
compositions containing
production
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69619868T
Other languages
English (en)
Other versions
DE69619868T2 (de
Inventor
Ivan Jakoczi
Daniel Bozsing
Simonek Ildiko Ratzne
Istvan Gacsalyi
Gabor Szenasi
Eva Schmidt
Kovacs Aniko Miklesne
Gorzo Andras Bilkei
Gabor Blasko
Istvan Gyertyan
Gabor Nemeth
Gyula Simig
Karoly Tihanyi
Andras Egyed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egyt Gyogyszervegyeszeti Gyar
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of DE69619868D1 publication Critical patent/DE69619868D1/de
Application granted granted Critical
Publication of DE69619868T2 publication Critical patent/DE69619868T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69619868T 1995-10-31 1996-10-25 Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung Expired - Fee Related DE69619868T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9503099A HUT76266A (en) 1995-10-31 1995-10-31 New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components
PCT/HU1996/000061 WO1997016429A1 (en) 1995-10-31 1996-10-25 Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the novel compounds

Publications (2)

Publication Number Publication Date
DE69619868D1 true DE69619868D1 (de) 2002-04-18
DE69619868T2 DE69619868T2 (de) 2002-10-10

Family

ID=10987317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619868T Expired - Fee Related DE69619868T2 (de) 1995-10-31 1996-10-25 Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung

Country Status (14)

Country Link
US (1) US6130215A (de)
EP (1) EP0901473B1 (de)
JP (1) JPH11514641A (de)
KR (1) KR19990067137A (de)
CN (1) CN1207733A (de)
AT (1) ATE214375T1 (de)
AU (1) AU707166B2 (de)
CZ (1) CZ112198A3 (de)
DE (1) DE69619868T2 (de)
HU (1) HUT76266A (de)
NZ (1) NZ320522A (de)
PL (1) PL327461A1 (de)
SK (1) SK283489B6 (de)
WO (1) WO1997016429A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
KR20020016872A (ko) 1999-06-29 2002-03-06 사바 키스 ; 아틸라 만디 야노스 템페 ; 기울라 시미그 신규한 피페라지닐알킬티오피리미딘 유도체, 그것을함유하는 약제 조성물, 및 활성성분의 제조방법
US20040014966A1 (en) * 2000-06-20 2004-01-22 Jacobsen Eric Jon Bis-arylsulfones
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
US6586592B2 (en) 2000-06-20 2003-07-01 Pharmacia & Upjohn Company Bis-arylsulfones
DE112009001776B4 (de) 2008-07-30 2021-01-21 Asahi Kasei Chemicals Corporation Verfahren zur Herstellung von Cycloolefin und Vorrichtung zur Herstellung desselben
US10315655B2 (en) 2017-03-07 2019-06-11 Deere & Company Vehicle control based on soil compaction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792206A (de) * 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
EP0202654A3 (de) * 1985-05-20 1987-12-16 E.R. Squibb & Sons, Inc. 5-Carboxy-1,4-dihydropyrimidinderivate

Also Published As

Publication number Publication date
CZ112198A3 (cs) 1998-09-16
EP0901473B1 (de) 2002-03-13
JPH11514641A (ja) 1999-12-14
AU7326296A (en) 1997-05-22
HU9503099D0 (en) 1995-12-28
SK47598A3 (en) 1998-12-02
HUT76266A (en) 1997-07-28
SK283489B6 (sk) 2003-08-05
CN1207733A (zh) 1999-02-10
US6130215A (en) 2000-10-10
PL327461A1 (en) 1998-12-07
DE69619868T2 (de) 2002-10-10
AU707166B2 (en) 1999-07-01
NZ320522A (en) 1999-03-29
KR19990067137A (ko) 1999-08-16
WO1997016429A1 (en) 1997-05-09
EP0901473A1 (de) 1999-03-17
ATE214375T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
DE69723869D1 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE69725608D1 (de) Indolin-2-one derivate, verfahren zu ihrer herstellung und dieseenthaltende arzneimittel
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2176668A1 (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
DE69526726T2 (de) Tetrasubstituierte imidazolderivate, verfahren zu ihrer herstellung, ihre anwendung als medikamente und diese enthaltende pharmazeutischen zusammensetzungen
DE69619868D1 (de) Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
ATE417831T1 (de) Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ATE10841T1 (de) Tricyclische thiazolyloxamidsaeuren und derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
DE69917668D1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
ATE421961T1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
ATE73807T1 (de) Neue benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte.
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
ES2123796T3 (es) Derivados de acidos fosfono-succinicos y su utilizacion como medicamentos.
ATE69809T1 (de) Leukotrienantagonisten, verfahren zu ihrer herstellung, ihre anwendung zur behandlung von krankheiten.
DE59504643D1 (de) Neue phosphanoxide, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
IT1258788B (it) Derivati solforati di acidi biliari
PT950053E (pt) Novos derivados de benzoilalquil-1,2,3,6-tetra-hidropiridinas
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee